A review of bevacizumab in the treatment of malignant pleural mesothelioma.

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive cancer with poor prognosis. Systemic chemotherapy is the primary treatment modality for the majority of patients. VEGF plays a key mitogen for MPM cells physiopathology. Bevacizumab, a monoclonal anti-VEGF antibody, was a rational approach to be tested in MPM. Based on the results of the Phase III IFCT-0701 mesothelioma avastin cisplatin pemetrexed study, cisplatin-pemetrexed-bevacizumab is now the accepted standard in France. The National Comprehensive Cancer Network guidelines have also included this combination as an option for standard front-line therapy. This review summarized the efficacy and safety data of bevacizumab in the treatment of patients with MPM.

• Authors: Solenn Brosseau, Sandra Assoun, Charles Naltet, Christelle Steinmetz, Valérie Gounant, Gérard Zalcman
• Journal: Future oncology (London, England) (Future Oncol) Vol. 13 Issue 28 Pg. 2537-2546 (Dec 2017) ISSN: 1744-8301 [Electronic] England
• PMID: 29086616 (Publication Type: Journal Article, Review)

Chemical References

• Angiogenesis Inhibitors
• Antineoplastic Agents, Immunological
• Bevacizumab

Topics

• Angiogenesis Inhibitors (chemistry, pharmacology, therapeutic use)
• Animals
• Antineoplastic Agents, Immunological (chemistry, pharmacology, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Bevacizumab (chemistry, pharmacology, therapeutic use)
• Clinical Trials as Topic
• Drug Evaluation, Preclinical
• Humans
• Lung Neoplasms (drug therapy, mortality, pathology)
• Mesothelioma (drug therapy, mortality, pathology)
• Mesothelioma, Malignant
• Molecular Targeted Therapy
• Pleural Neoplasms (drug therapy, mortality, pathology)
• Randomized Controlled Trials as Topic
• Treatment Outcome